Core Viewpoint - Shanghai Xuantai Pharmaceutical Technology Co., Ltd. has successfully renewed the inclusion of its product, Sitagliptin Metformin Extended-Release Tablets (II), in the National Medical Insurance Catalog (2025), reflecting the recognition of its clinical value by the National Healthcare Security Administration [1][2]. Group 1: Product Information - The product Sitagliptin Metformin Extended-Release Tablets (II) has been included in the National Medical Insurance Catalog (2025) under a national negotiation renewal format [1]. - The inclusion is expected to enhance the affordability and accessibility of the drug for patients, thereby promoting its market expansion and increasing sales volume [1]. Group 2: Impact on the Company - The renewal of the product's inclusion in the National Medical Insurance Catalog is anticipated to have a positive impact on the company's long-term operational development [1]. - The company plans to actively cooperate in implementing the medical insurance policy to benefit more patients [1]. Group 3: Implementation Timeline - The National Medical Insurance Catalog (2025) will officially take effect on January 1, 2026, with specific details on reimbursement standards and policies to be announced by relevant government departments [2].

截至2025年12月8日收盘，宣泰医药（688247）报收于10.37元，较前一交易日上涨0.39%，最新总市值 为47.01亿元。该股当日开盘10.36元，最高10.4元，最低10.3元，成交额达1844.61万元，换手率为 0.39%。 最新公告列表 《自愿披露关于公司产品续约纳入国家医保目录的公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 近日，上海宣泰医药科技股份有限公司发布公告，其产品西格列汀二甲双胍缓释片（II）以国谈续约形 式纳入《国家基本医疗保险、生育保险和工伤保险药品目录（2025年）》，医保支付标准维持3.47元/ 片不变，协议有效期为2026年1月1日至2027年12月31日。该药品为口服复方降糖药，分类为乙类。此次 续约有助于提升药品可及性和市场推广，对公司长期经营发展具有积极影响，但短期内业绩影响存在不 确定性。 ...

宣泰医药公告，公司产品西格列汀二甲双胍缓释片（II）以国谈续约的形式纳入《国家基本医疗保险、 生育保险和工伤保险药品目录（2025年）》。 ...

Core Viewpoint - XuanTai Pharmaceutical (688247.SH) has successfully renewed the inclusion of its product, Sitagliptin Metformin Extended-Release Tablets (II), in the National Medical Insurance Catalog (2025) through a national negotiation process, indicating recognition of the drug's clinical value by the National Healthcare Security Administration [1] Summary by Relevant Categories Product Inclusion - The Sitagliptin Metformin Extended-Release Tablets (II) have been renewed for inclusion in the National Medical Insurance Catalog, reflecting the government's acknowledgment of its clinical value [1] Market Impact - The inclusion in the insurance catalog is expected to enhance the affordability and accessibility of the drug for patients, which will facilitate market promotion and increase sales scale [1] Long-term Development - This development is viewed positively for the company's long-term operational growth, as it aligns with the goal of benefiting more patients through improved healthcare policies [1]